

****New release October 2011****

MarketVIEW: Travelers diarrhea vaccines (CAT: VAMV028)

Proposal No/#PO	:	[Enter client specific #PO]
Product Name	:	MarketVIEW: Travelers' diarrhea vaccines – Global market forecast
Project Initiation Date	:	n/a
Billable days	:	n/a
Initiator(s)	:	[Enter client name, function and address]
Therapeutic Area	:	<i>Novel travel/endemic vaccines</i>
Product (if applicable)	:	CAT No: VAMV028, published October 2011

Background

Travelers' diarrhea (TD), although mainly a self-limiting illness, affects a large percentage of individuals when visiting endemic countries often causing disturbance of itinerary, inconvenience and additional cost. In extreme cases TD can result in hospitalization, especially in travelers with chronic illnesses. Accumulating evidence also suggests that TD may cause post-infectious irritable bowel (IBS) syndrome in around 3% of cases.

Enterotoxigenic *Escherichia coli* bacteria are a common cause of TD (~45% of cases). The pathogen has been a primary focus of new TD vaccine development for many years with numerous approaches taken but with little success. Currently the marketed cholera vaccine Dukoral[®] (J&J/Crucell) has been shown to demonstrate some protection against ETEC induced diarrhea although it is short-lived prompting some countries not to fully recommend its use for TD. Clearly a new TD vaccine with higher efficacy, broader pathogen coverage and longer protection is required not only for travelers but children in developing countries.

This **MarketVIEW** product is a comprehensive opportunity assessment investigating the commercial potential of hypothetical new TD vaccine for the Western travelers visiting TD endemic countries. The product consists of a detailed Executive presentation covering all relevant topics to new TD vaccine commercialization including ideal target product profile, research and clinical development issues and potential impact on Dukoral[®]. Also included is a detailed MS Excel value/volume demand forecast to 2030 for all relevant countries with sensitivity analysis.

This product is an ideal tool to aid early stage decision making in new TD vaccine development.

Methodology

VacZine Analytics has closely monitored all significant source material pertaining to Travelers' diarrhea disease epidemiology/dynamics, current treatments and novel immunotherapeutics (pipeline). Example, secondary source materials used are literature articles, government websites/databases, medical bodies and associations, conference proceedings and previously analyses (where publically available). Previously published research by **VacZine Analytics** in field of bacterial vaccines has also been utilised. ***See Bibliography for exact sources.

PRODUCT CONTENTS:

Published October 2011 (CAT No: VAMV028)

****This product is composed of a forecast model and summary presentation

Contents – Summary presentation (MS PowerPoint based)

Contents
Author's Note
Executive summary
New Travelers' diarrhea (TD) vaccine – key model outputs
Travelers' diarrhea/cholera - vaccine market to 2030 (\$ 000s)
New Travelers' diarrhea vaccine: market by region to 2030 (\$ 000s)
New Travelers' diarrhea vaccine: volume by region to 2030 (\$ 000s)
New Travelers' diarrhea vaccine: key model sensitivities
Travelers' diarrhea - disease background
Travelers' diarrhea - overall risk factors
Travelers' diarrhea - risk areas
Travelers' diarrhea - causative pathogens (bacterial)¹
Travelers' diarrhea - causative pathogens (viral/parasites)¹
Travelers' diarrhea - regional distribution of most common pathogens¹
Travelers' diarrhea - economic burden
Travelers' diarrhea - impact on military
Travelers' diarrhea - current management/vaccination
Travelers' diarrhea - commonly used drugs¹
Travelers' diarrhea - vaccination (Dukoral)
Dukoral - mechanism of action
Dukoral - product profile¹
Dukoral - efficacy against ETEC
Designing a new Travelers' diarrhea vaccine
Background to Travelers' diarrhea vaccine development
Summary of vaccine approaches to date
Travelers' diarrhea vaccine antigens and immunology
Distribution of ETEC LT/ST antigens in global isolates
Distribution of ETEC CF antigens in global isolates
Comments on new TD vaccine strategies
Coverage of a hypothetical new TD vaccine
Ideal TD vaccine - target product profile
Required effectiveness of an ETEC vaccine (travelers)

CONTINUED.....

TD vaccines: current R&D pipeline
ETEC specific vaccines: notes on development
ETEC specific vaccines: research priorities
New TD vaccines - incorporating Shigella
New TD vaccine – assessing commercial value
Estimated Trips to TD endemic regions (2011)
TD travelers segment: overview of modeling strategy
Model assumptions: new TD vaccine - US/CAN
Model assumptions: new TD vaccine - UK/France/Germany
Model assumptions: new TD vaccine - Italy/Spain/Nordic
Model assumptions: new TD vaccine - Aust/Korea/Japan
Dukoral vaccine estimated penetration rates (2010 – 2018 onwards)
Vaccine prices used in model (2010 – 2018 onwards)
New TD vaccine: potential impact on Dukoral
Dukoral decline rates used in model (2018 onwards)
New TD vaccine: comparison with BVGH analysis (2011)
Major model caveats and limitations
A childhood ETEC vaccine – discussion of major issues
Order of evaluation for ETEC childhood vaccine
Predicted market value of a childhood ETEC vaccine
Appendix I – backup and source material
Notes on Shigellosis
Focus on ETEC pathogenesis
Comparing ETEC with Cholera
Case study: whole cell ETEC/CTB
Example penetration rates of travel vaccines
Travel vaccine penetration rates: Japan
Dukoral - background (market/financial)
Market value estimation for Cholera vaccine
Dukoral vaccine penetration rates (Crucell)
Bibliography
Disclaimer

About VacZine Analytics

PAGES: ~80 MS PowerPoint slides, fully referenced/sourced. Available in .pdf form

CONTINUED.....

Contents – Vaccine demand model (MS Excel-based)

Title sheet
CHARTS (VAL)
CHARTS (VOL)
Sensitivity analysis
Grand value summary
New TD – value summary
Dukoral – value summary (estimated)
Global price summary
New TD vaccine – volume summary
Dukoral volume summary (estimated)
Country worksheets →
North America and EU
US Travelers (TD)
Canada Travelers (TD)
UK Travelers (TD)
France Travelers (TD)
Germany Travelers (TD)
Italy Travelers (TD)
Spain Travelers (TD)
Denmark Travelers (TD)
Finland Travelers (TD)
Norway Travelers (TD)
Sweden Travelers (TD)
Rest of World →
Australia Travelers (TD)
Japan Travelers (TD)
S Korea Travelers (TD)
Source material
Trips to TD endemic countries
TD Trips – CHARTS
VA Travel data
Peds Travel
Travel planning and duration
Example travel market sizes
Travel vaccine penetration rates (Japan)
Back page

WORKSHEETS: ~40

PRODUCT COST:

VacZine Analytics will grant a [enter region] license to [enter client name], for the price of:

- o USD \$8995.00/ GBP £5600.00[#] (Region license)*

*A region is North America, Europe or ROW


For orders in the UK, VAT at 20% will be added to final invoice total

#Indicative - conversions to other currencies will be effected on date of transaction.

HOW TO ORDER:

To order please contact your region account manager or order direct at orders@vaczine-analytics.com

This report can also be purchased on-line. Please review the **TERMS and CONDITIONS** of purchase.



VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and the “**spiral logo**” are UK Registered Trademarks, 2009

BIBLIOGRAPHY:

1. Crucell Corporate Website. Dukoral product section. Available at: <http://www.crucell.com/Products/Dukoral>. Accessed October 2011
2. Al Abri SS et al. Traveller's diarrhoea. *Lancet Infect Dis* 2005; 5: 349 -60
3. Steffen R, van der Linde F, Gyr K, Schar M. Epidemiology of diarrhoea in travelers. *JAMA* 1983; **249**: 1176–80.
4. Ericsson CD. Travelers' diarrhea. Epidemiology, prevention, and self-treatment. *Infect Dis Clin North Am* 1998; 12: 285–303.
5. DuPont HL, Capsuto EG. Persistent diarrhea in travelers. *Clin Infect Dis* 1996; 22: 124–28.
6. Ardley C et al. Traveller's diarrhoea. 2009. Syndromic Presentations. *Medicine* 38.1
7. Dukoral® . Oral inactivated Travelers' diarrhea and cholera vaccine. Product Monograph. Sanofi Pasteur Ltd (Canada). Available at: https://www.vaccinshoppecanada.com/secure/pdfs/ca/Dukoral®_e.pdf. Accessed September 2011
8. Sack DA., et al. Cholera. *Lancet* 2004; 363: 223 – 33
9. Ryan ET et al. *J Travel Med* 1994;8(2): 82-91
10. Kollaritsch H. Traveller's diarrhea among Austrian tourists in warm climate countries: I. *Epidemiology. Eur J Epidemiol* 1989; 5: 74–81.
11. Steffen R. Travel medicine—prevention based on epidemiological data. *Trans R Soc Trop Med Hyg* 1991; 85: 156–62.
12. Gascon J, Vila J, Valls ME, et al. Etiology of traveller's diarrhoea in Spanish Travelers to developing countries. *Eur J Epidemiol* 1993; 9: 217–23
13. Map taken from: Intercell AG. Corporate Presentation, November 9th 2009. Available at: <http://www.intercell.com>. Accessed September 2011
14. US Centers For Disease Control and Prevention. Traveler's Diarrhea. Yellow Book. Available at: <http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-2-the-pre-travel-consultation/travelers-diarrhea.htm>. Accessed September 2011
15. Ardley C et al. Traveller's diarrhoea. 2009. Syndromic Presentations. *Medicine* 38.1
16. Steffen R et al. Vaccination against enterotoxigenic *Escherichia coli*, a cause of travelers' diarrhea. *Journal of Travel Medicine*. 2005;12(2):102–107
17. Meraz IM., et al. Enterotoxigenic *Escherichia coli* and diffusely adherent *E. coli* as likely causes of a proportion of pathogen-negative travelers' diarrhea—a PCR-based study. *Journal of Travel Medicine*. 2008;15(6):412– 418.
18. Ansdell VE et al., Prevention and empiric treatment of traveler's diarrhea. *Med Clin North Am*. 1999; 83: 945 - 73
19. Wang M, Szucs TD, Steffen R. Economic aspects of travelers' diarrhea. *Journal of Travel Medicine*. 2008;15(2):110 – 118.
20. Sanchez JL et al (1998). Diarrheal disease incidence and morbidity among United States military personnel during short-term missions overseas. *Am J Trop Med Hyg* 58, 299–304
21. Connor P, Farthing MJ (1999). Travelers' diarrhoea: a military problem? *J R Army Med Corps* 145, 95–101.
22. Riddle MS et al. Development of a travelers' diarrhea vaccine for the military: How much is an ounce of prevention really worth? *Vaccine*. 2008;26(20):2490–2502.
23. Adachi JA, Ostrosky-Zeichner L, DuPont HL, Ericsson CD. Empirical antimicrobial therapy for traveler's diarrhea. *Clin Infect Dis* 2000; 31: 1079–83.
24. de Bruyn G, Hahn S, Borwick A. Antibiotic treatment for Travelers' diarrhoea. *Cochrane Database Syst Rev* 2000; 3: CD002242
25. Peltola H et al. Prevention of travelers' diarrhea by oral B-subunit/whole cell cholera vaccine. *Lancet* 1991; 338: 1285-9
26. Lopez-Gigosos R et al. Effectiveness in prevention of traveler's diarrhea by an oral cholera vaccine WC/rBS. *Travel Medicine and Infectious Diseases*. 2007 5, 380-384
27. Torrell JMR et al. Reduction of Travelers' diarrhoea by WC/rBS oral cholera vaccine in young, high-risk Travelers. *Vaccine*. 2009;27(30):4074–4077.
28. Connor BA et al. In Arguin PA et al. Traveler's health yellow book. Health information for international travel. 2005-2006. Atlanta. US Department of Health and Human Services, Public Health Service, CDC, 2005.
29. Walker RI et al. Analysis of strategies to successfully vaccinate infants in developing countries against ETEC disease. *Vaccine* 25 (2007) 2545 - 2566
30. Levine MM, Nalin DR, Hoover DL, Bergquist EJ, Hornick RB, Young CR. Immunity to enterotoxigenic *Escherichia coli*. *Infect Immun* 1979;23:729–36.
31. Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Molbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic *Escherichia coli*: longitudinal study. *Lancet* 2003;362(9380):286–91.
32. Sizemore DR, Roland KL, Ryan US. Enterotoxigenic *Escherichia coli* virulence factors and vaccine approaches. *Expert Rev Vaccines* 2004;3:585–95.
33. Wolf M. Occurrence, distribution, and associations of O and H serogroups, colonization factor antigens, and toxins of enterotoxigenic *Escherichia coli*. *Clin Microbiol Rev* 1997;10(4):569–84.
34. Qadri F et al. Prevalence of toxin types and colonization factors in ETEC for humans. *Infect Immun* 1975;12:656-67

CONTINUED.....

35. Freedman DJ, Tacket CO, Delehanty A, Maneval DR, Nataro J, Crabb JH. Milk immunoglobulin with specific activity against purified colonization factor antigens can protect against oral challenge with enterotoxigenic *Escherichia coli*. *J Infect Dis* 1998;177(3):662–7.
36. Tacket CO, Lososky G, Link H, Hoang Y, Guesry P, Hilpert H, et al. Protection by milk immunoglobulin concentrate against oral challenge with enterotoxigenic *Escherichia coli*. *N Engl J Med* 1988;318(19):1240–3.
37. Rendón M, Saldaña Z, Erdem A, Monteiro-Neto V, Vázquez A, Kaper J, et al. Commensal and pathogenic *Escherichia coli* use a common pilus adherence factor for epithelial cell colonization. *Proc Natl Acad Sci U S A* 2007;104(25):10637–42.
38. Fleckenstein J, Roy K, Fischer J, Burkitt M. Identification of a twopartner secretion locus of enterotoxigenic *Escherichia coli*. *Infect Immun* 2006;74(4):2245–58.
39. Roy K, Hilliard G, Hamilton D, Luo J, Ostmann M, Fleckenstein J. Enterotoxigenic *Escherichia coli* EtpA mediates adhesion between flagella and host cells. *Nature* 2009;457(7229):594–8.
40. Fleckenstein J, Hardwidge P, Munson G, Rasko D, Sommerfelt H, Steinsland H. Molecular mechanisms of enterotoxigenic *Escherichia coli* infection. *Microbes Infect* 2010;12(2):89–98.
41. Isidean SD et al. A systematic review of ETEC epidemiology focusing on colonization factor and toxin expression. *Vaccine* 29 (2011): 6167 – 6168
42. The Case for Investment in Enterotoxigenic *Escherichia coli* vaccines. March 2011. PATH & BVGH. Available at: <http://www.path.org/files/VAC-etec-investment-rpt.pdf>. Accessed October 2011
43. Spira WM, Sack RB, Froehlich JL. Simple adult rabbit model for *Vibrio cholerae* and enterotoxigenic *Escherichia coli* diarrhea. *Infect Immun* 1981;32:739–47.
44. Sack RB, Kline RL, Spira WM. Oral immunization of rabbits with enterotoxigenic *Escherichia coli* protects against intrainestinal challenge. *Infect Immun* 1988;56:387–94.
45. Rao MR, Wierzbza TF, Savarino SJ, Abu-Elyazeed R, El-Ghoreb N, Hall ER, et al. Serologic correlates of protection against enterotoxigenic *Escherichia coli* diarrhea. *J Infect Dis* 2005;191:562–70.
46. The World Health Organisation (WHO). Initiative For Vaccine Research (IVR). Diarrhoeal Diseases. Available at: http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index6.html. Accessed October 2011
47. S.B. Formal et al. Effect of prior infection with *Shigella flexneri* 2a on the resistance of monkeys to subsequent infection with *Shigella sonnei*. *J. Infect. Dis* 164 (1991) 534e537.
48. The World Health Organisation (WHO). Initiative For Vaccine Research (IVR). Diarrhoeal Diseases. Available at: http://www.who.int/vaccine_research/diseases/diarrhoeal/en/index6.html. Accessed October 2011
49. Barry EM et al. Immune responses elicited against multiple enterotoxigenic *Escherichia coli* fimbriae and mutant LT expressed in attenuated *Shigella* vaccine strains.. *Vaccine* (2003) 21: (5-6), 333-40
50. Güereña-Burgueño F et al. Safety and immunogenicity of a prototype enterotoxigenic *Escherichia coli* vaccine administered transcutaneously. *Infect Immun*. 2002. 70(4):1874-80
51. World Tourism Organisation. Factbook data. Available at: <http://www.e-unwto.org>. Accessed August 2011
52. ITA Office of travel & tourism industries. U.S. Citizen Air Traffic to Overseas Regions, Canada & Mexico 2009. Available at: <http://tinet.ita.doc.gov/view/m-2009-O-001/index.html>. Accessed August 2011
53. UK Office For National Statistics. Travel Trends. Edition Number 2009. Available at: http://www.statistics.gov.uk/downloads/theme_transport/travel-trends09.pdf. Accessed August 2011
54. Canada Tourist Board. Tourism Snapshot. 2010 Year in Review. Available at: http://en-corporate.canada.travel/sites/default/files/pdf/yearinreview_2010_eng_final_rev.pdf. Accessed August 2011
55. The Boston Consulting Group. Market Assessment for Malaria Vaccines. January 2005. Available at: http://www.malariavaccine.org/files/Market-Assessment-18Jan05-LB-BOS_000.pdf. Accessed December 2010
56. UK Civil Aviation Authority Figures 2009, Heathrow airport/leisure. Available at: <http://www.caa.co.uk/docs/81/2009CAAPaxSurveyReport.pdf>. Accessed October 2011
57. Hamada A, Past, present and future of travel medicine in Japan, *Travel Medicine and Infectious Disease* (2010), doi:10.1016/j.tmaid.2010.09.006
58. Svennerholm AM, Steele D: Microbial-gut interactions in health and disease. *Progress in enteric vaccine development*. *Best Pract Res Clin Gastroenterol* 2004, 18:421-445.
59. Refs within. Walker RI et al. Analysis of strategies to successfully vaccinate infants in developing countries against ETEC disease. *Vaccine* 25 (2007) 2545 - 2566
60. K.L. Kotloff, J.P. Winickoff, B. Ivanoff, J.D. Clemens, D.L. Swerdlow, P.J. Sansonetti, G.K. Adak, M.M. Levine, Global burden of *Shigella* infections: implication for vaccine development and implementation of control strategies, *Bull. World Health Organ* 77 (1999) 651e666.
61. L. Von Seidlen et al, A multicentre study of *Shigella* diarrhea in six Asian countries: disease burden, clinical manifestations, and microbiology, *PLoS Med* 3 (2006) e353.

CONTINUED.....

62. Steffen R, Castelli F, Dieter Nothdurft H, Rombo L, Jane Zuckerman N. Vaccination against enterotoxigenic Escherichia coli, a cause of travelers' diarrhea. *J Travel Med* 2005;12(2):102–7.
63. Wenneras C, Erling V. Prevalence of enterotoxigenic Escherichia coli associated diarrhoea and carrier state in the developing world. *J Health Popul Nutr* 2004;22(4):370–82
64. Ericsson CD. Traveler's diarrhea. *Int J Antimicrobial Agents*. 2003; 21: 116-24
65. Sanchez J et al. Virulence factors, pathogenesis and vaccine protection in cholera and ETEC diarrhea. *Cur Opin Immunol* 2005; 17:388-398
66. Jertborn M, Ahren C, Holmgren J, Svennerholm AM. Safety and immunogenicity of an oral inactivated enterotoxigenic Escherichia coli vaccine. *Vaccine* 1998;16:255–60.
67. Savarino SJ, Brown FM, Hall E, Bassily S, Youssef F, Wierzba T, Escherichia coli-cholera toxin B subunit vaccine in Egyptian adults. *J Infect Dis* 1998;177:796–9.
68. Qadri F, Wenneras C, Ahmed F, Asaduzzaman M, Saha D, Albert MJ, et al. Safety and immunogenicity of an oral, inactivated enterotoxigenic Escherichia coli plus cholera toxin B subunit vaccine in Bangladeshi adults and children. *Vaccine* 2000;18:2704–12.
69. Wiedermann G, Kollaritsch H, Kundi M, Svennerholm AM, Bjare U. Double-blind, randomized, placebo controlled pilot study evaluating efficacy and reactogenicity of an oral ETEC B-subunit-inactivated whole cell vaccine against travelers' diarrhea (preliminary report). *J Travel Med* 2000;7:27–9.
70. Sack DA et al. Randomized, double blind, safety and efficacy of a killed oral vaccine for ETEC diarrhea of travelers to Guatemala and Mexico. *Vaccine* (2007) 25: 4392-4400
71. Intercell AG. Annual General Meeting Presentation. June 25th 2010. Available at: www.intercell.com. Accessed April 2011
72. Crucell Corporate Website. Dukoral[®]. Available at: <http://www.crucell.com/Products/Dukoral>. Accessed October 2011
73. 3i and SEB Företagsinvest divest stakes in SBL Vaccines in sale to Crucell. Press release 21 November 2006. Available at: <http://www.3i.com/media/press-releases/3i-and-seb-foretagsinvest-divest-stakes-in-sbl-vaccines-in-sale-to-crucell.html>. Accessed October 2011
74. Crucell Fourth Quarter Results 2009. Available at: <http://www.huginonline.nl/CRXL/files/20100209b.pdf> Accessed October 2011
75. Crucell Annual Report. 2008. Available at: <http://www.crucell.com>. Accessed October 2011
76. Crucell Investor Day. March 12th 2008. Available at: <http://hugin.info/132631/R/1317501/307347.pdf>. Accessed October 2011
77. Crucell Press Release. August 26th 2008. Available at: <http://www.marketwire.com/press-release/Crucell-move-Dukoral-rCTB-bulk-production-formulation-fill-finish-activities-from-Sweden-893199.htm>. Accessed October 2011
78. Crucell Second Quarter Results 2009. Available at: <http://hugin.info/132631/R/1438369/382923.pdf>. Accessed October 2011
79. World Health Organization. The immunological basis for Immunization Series. Module 14. Cholera. Available at: http://whqlibdoc.who.int/publications/2010/9789241599740_eng.pdf. Accessed October 2011
80. Intercell AG. Corporate Presentation, November 9th 2010. Q3 Results. Available at: <http://www.intercell.com>. Accessed April 2011
81. Cuccell Investor and Analyst Day. March 12th 2008. Available at: <http://hugin.info/132631/R/1208066/249155.pdf>. Accessed October 2011
82. Crucell Corporate Website. Dukoral product section. Available at: <http://www.crucell.com/Products/Dukoral>. Accessed October 2011

TERMS and CONDITIONS:

VacZine Analytics – a trading division of Assay Advantage Ltd UK Company Number: 5807728 (Herein referred to as “The Company”). (Herein [enter client name] to as “The Client”).

1. This finished research product is provided is provided as a Service. Any additional Service required by the client will be subject to a new proposal being prepared.
2. The Service will commence after written (e-mail) or Fax confirmation stating the Client's acceptance of the Service according the description proposed by the Company.
3. **Cancellation policy.** The Company's cancellation policies are in accordance with the EU Consumer Protection (Distance Selling) Regulations 2000 (DSRs). Prior to acceptance of an order the Company will make available written information regarding Clients cancellation rights. This is posted on the Company website and is available for public review.
4. **Cancellation rights:** For finished documents - a Clients cancellation rights will last for **seven working days** counting from the day that the order was concluded. If the Services i.e. provision of the documents has taken place with the Clients agreement before this period the Client's cancellation rights have ended.
5. Invoicing will **100%** after submission of deliverables to the Client in a form reasonably acceptable to the Client.
6. If not purchased on line invoices are payable within **thirty days** of the invoice date.
7. All proposals are quoted in **\$USD dollars or £GBP** and invoices are to be settled in the same currency.
8. The Company agrees not to disclose to any third party confidential information acquired in the course of providing the services listed without the prior written consent of the Client. Exception occurs when the information is already in the public domain or when disclosure is necessary to help the Company's employees and agents with the performance of the Company's obligations to achieve satisfactory completion of the project and approved in writing by the Client.
9. Force Majeure: The Company will not be liable for any delay or failure to perform any obligation under this Agreement insofar as the performance of such obligation is prevented by an event beyond our reasonable control, included by not limited to, earthquake, fire, flood or any other natural disaster, labour dispute, riot, revolution, terrorism, acts of restraint of government or regulatory authorities, failure of computer equipment and failure or delay of sources from which data is obtained.
10. Please also refer to Master **TERMS and CONDITIONS** available upon request.

VacZine Analytics

Warren House
Bells Hill
Bishops Stortford
Herts
CM23 2NN
United Kingdom
Tel: +44 (0) 1279 654514 / +44 (0) 7952470582 / Fax: +44 (0) 1279 655926
E-mail: info@vacZine-analytics.com

About VacZine Analytics:

VacZine Analytics is an established strategic research agency based in the United Kingdom. Its aim is to provide disease and commercial analysis for the vaccine industry and help build the case for developing new vaccines and biologics.

For more information please visit our website www.vacZine-analytics.com

VacZine Analytics (R) is a trading division of Assay Advantage Ltd, UK Company Number: 5807728

VacZine Analytics (R) and “the spiral logo” are UK Registered Trademarks, 2009